Paetsch Ingo, Huber Michael E, Bornstedt Axel, Schnackenburg Bernhard, Boesiger Peter, Stuber Matthias, Fleck Eckart, Cavagna Friedrich, Nagel Eike
Clinic of Internal Medicine/Cardiology, German Heart Institute-Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
J Magn Reson Imaging. 2004 Aug;20(2):288-93. doi: 10.1002/jmri.20099.
To evaluate gadocoletic acid (B-22956), a gadolinium-based paramagnetic blood pool agent, for contrast-enhanced coronary magnetic resonance angiography (MRA) in a Phase I clinical trial, and to compare the findings with those obtained using a standard noncontrast T2 preparation sequence.
The left coronary system was imaged in 12 healthy volunteers before B-22956 application and 5 (N = 11) and 45 (N = 7) minutes after application of 0.075 mmol/kg of body weight (BW) of B-22956. Additionally, imaging of the right coronary system was performed 23 minutes after B-22956 application (N = 6). A three-dimensional gradient echo sequence with T2 preparation (precontrast) or inversion recovery (IR) pulse (postcontrast) with real-time navigator correction was used. Assessment of the left and right coronary systems was performed qualitatively (a 4-point visual score for image quality) and quantitatively in terms of signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), vessel sharpness, visible vessel length, maximal luminal diameter, and the number of visible side branches.
Significant (P < 0.01) increases in SNR (+42%) and CNR (+86%) were noted five minutes after B-22956 application, compared to precontrast T2 preparation values. A significant increase in CNR (+40%, P < 0.05) was also noted 45 minutes postcontrast. Vessels (left anterior descending artery (LAD), left coronary circumflex (LCx), and right coronary artery (RCA)) were also significantly (P < 0.05) sharper on postcontrast images. Significant increases in vessel length were noted for the LAD (P < 0.05) and LCx and RCA (both P < 0.01), while significantly more side branches were noted for the LAD and RCA (both P < 0.05) when compared to precontrast T2 preparation values.
The use of the intravascular contrast agent B-22956 substantially improves both objective and subjective parameters of image quality on high-resolution three-dimensional coronary MRA. The increase in SNR, CNR, and vessel sharpness minimizes current limitations of coronary artery visualization with high-resolution coronary MRA.
在一项I期临床试验中评估钆贝酸(B - 22956),一种基于钆的顺磁性血池造影剂,用于对比增强冠状动脉磁共振血管造影(MRA),并将结果与使用标准非对比T2准备序列获得的结果进行比较。
对12名健康志愿者在应用B - 22956之前、应用0.075 mmol/kg体重(BW)的B - 22956后5分钟(N = 11)和45分钟(N = 7)对左冠状动脉系统进行成像。此外,在应用B - 22956后23分钟(N = 6)对右冠状动脉系统进行成像。使用具有T2准备(对比前)或反转恢复(IR)脉冲(对比后)并带有实时导航校正的三维梯度回波序列。对左、右冠状动脉系统的评估采用定性(图像质量的4分视觉评分)和定量评估,包括信噪比(SNR)、对比噪声比(CNR)、血管清晰度、可见血管长度、最大管腔直径和可见侧支数量。
与对比前T2准备值相比,应用B - 22956后5分钟,SNR显著增加(+42%),CNR显著增加(+86%)(P < 0.01)。对比后45分钟,CNR也显著增加(+40%,P < 0.05)。对比后图像上血管(左前降支动脉(LAD)、左冠状动脉回旋支(LCx)和右冠状动脉(RCA))也显著更清晰(P < 0.05)。LAD的血管长度显著增加(P < 0.05),LCx和RCA的血管长度也显著增加(均P < 0.01),与对比前T2准备值相比,LAD和RCA可见的侧支显著更多(均P < 0.05)。
血管内造影剂B - 22956的使用显著改善了高分辨率三维冠状动脉MRA图像质量的客观和主观参数。SNR、CNR和血管清晰度的增加最大限度地减少了高分辨率冠状动脉MRA在冠状动脉可视化方面的当前局限性。